Loading
A phase 3 trial of Pembrolizumab in non-small-cell lung cancer and small-cell lung cancer, run by NovoCure GmbH, now recruiting.
LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC is a phase 3 interventional study registered as NCT06216301 by NovoCure GmbH, with 734 participants planned, started 2024-07-31 and due to reach its primary completion in 2028-10. Interventions recorded: NovoTTF-200T, Pembrolizumab, Platinum based chemotherapy. Conditions listed: Metastatic Non-small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Shares Novocure, Pembrolizumab, Immune checkpoint inhibitors.
Shares Novocure, Immune checkpoint inhibitors, Non-small-cell lung cancer.
Shares Novocure, Non-small-cell lung cancer.
Shares Novocure, Non-small-cell lung cancer.